Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00758589 | One Month Dose Response Study of AZD1981 in Asthma Patients Uncontrolled on Inhaled Steroids | PHASE2 | COMPLETED | 368 | — | — | Sep 1, 2008 | Jul 1, 2009 | Feb 26, 2014 | 21 | Argentina, Brazil +2 |
| NCT01265641 | To Investigate the Effects of AZD1981 on the QT Interval | PHASE1 | COMPLETED | 44 | — | — | Jan 1, 2011 | Apr 1, 2011 | Jun 28, 2011 | 1 | United Kingdom |
Mean mPEF during the treatment period (mean of the last 2 weeks of the treatment period)
| Arm | Type | Description |
|---|---|---|
| AZD1981 50 mg | EXPERIMENTAL | AZD1981 50 mg Twice Daily (Bid) |
| Placebo | PLACEBO_COMPARATOR | Placebo |
| AZD1981 400 mg | EXPERIMENTAL | AZD1981 400 mg Twice Daily (Bid) |
| AZD1981 1000 mg | EXPERIMENTAL | AZD1981 1000 mg Twice Daily (Bid) |
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | - |
| 3 | EXPERIMENTAL | - |
| 4 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| AZD1981 | DRUG | Oral tablet, 50 mg twice daily |
| Placebo | DRUG | - |
| AZD1981, 2000mg | DRUG | Single oral dose, tablets |
| AZD1981, 200mg | DRUG | Single oral dose, tablets |
| Moxifloxacin, 400mg | DRUG | Single oral dose, capsule |
Inclusion Criteria: * Six months history of asthma * Daily use of inhaled glucocorticosteroids * FEV1 40-85% of predicted normal * Reversibility; increase in FEV1 more than 12% and 200 mL post-bronchodilator Exclusion Criteria: * Other clinically relevant disease or disorders * History of smoking...